EP3618829C0 - Quinazoline-pyridine derivatives for the treatment of cancer-related disorders - Google Patents
Quinazoline-pyridine derivatives for the treatment of cancer-related disordersInfo
- Publication number
- EP3618829C0 EP3618829C0 EP18794742.9A EP18794742A EP3618829C0 EP 3618829 C0 EP3618829 C0 EP 3618829C0 EP 18794742 A EP18794742 A EP 18794742A EP 3618829 C0 EP3618829 C0 EP 3618829C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- quinazoline
- cancer
- treatment
- related disorders
- pyridine derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- AMJZJYLMKHTSDG-UHFFFAOYSA-N pyridine;quinazoline Chemical class C1=CC=NC=C1.N1=CN=CC2=CC=CC=C21 AMJZJYLMKHTSDG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762502391P | 2017-05-05 | 2017-05-05 | |
US201862624273P | 2018-01-31 | 2018-01-31 | |
PCT/US2018/030909 WO2018204661A1 (en) | 2017-05-05 | 2018-05-03 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3618829A1 EP3618829A1 (en) | 2020-03-11 |
EP3618829A4 EP3618829A4 (en) | 2021-01-06 |
EP3618829C0 true EP3618829C0 (en) | 2023-06-07 |
EP3618829B1 EP3618829B1 (en) | 2023-06-07 |
Family
ID=64016681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18794742.9A Active EP3618829B1 (en) | 2017-05-05 | 2018-05-03 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
Country Status (9)
Country | Link |
---|---|
US (1) | US11045472B2 (en) |
EP (1) | EP3618829B1 (en) |
JP (1) | JP7295034B2 (en) |
CN (1) | CN110612100B (en) |
ES (1) | ES2953349T3 (en) |
PL (1) | PL3618829T3 (en) |
TW (1) | TWI789393B (en) |
UY (1) | UY37725A (en) |
WO (1) | WO2018204661A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2951809T3 (en) * | 2017-05-17 | 2023-10-25 | Arcus Biosciences Inc | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
CN109293586A (en) * | 2018-11-22 | 2019-02-01 | 云南师范大学 | A method of halogen benzoic acid synthesizes quinazolinones under microwave condition in ammonium hydroxide |
WO2020146563A1 (en) * | 2019-01-10 | 2020-07-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy |
IL295569A (en) | 2020-03-19 | 2022-10-01 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
PE20231078A1 (en) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | ANTI-TIGIT ANTIBODIES |
US11649261B2 (en) | 2020-06-17 | 2023-05-16 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
EP4423069A1 (en) | 2021-10-29 | 2024-09-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1397364T3 (en) * | 2001-05-24 | 2007-11-26 | Lilly Co Eli | Newly disclosed pyrrole derivatives as pharmaceutical agents |
TWI330183B (en) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
ES2311759T3 (en) * | 2003-05-06 | 2009-02-16 | Cv Therapeutics, Inc. | XANTINA DERIVATIVES AS ANTAGONISTS OF ADENOSINE A2B RECEIVER. |
BRPI0417478A (en) * | 2003-12-15 | 2007-05-08 | Almirall Prodesfarma Ag | 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
TW200813056A (en) * | 2006-06-29 | 2008-03-16 | King Pharmaceuticals Res Dev Inc | Adenosine A2B receptor antagonists |
TWI473614B (en) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
WO2010033906A2 (en) * | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
-
2018
- 2018-05-03 CN CN201880029680.6A patent/CN110612100B/en active Active
- 2018-05-03 ES ES18794742T patent/ES2953349T3/en active Active
- 2018-05-03 EP EP18794742.9A patent/EP3618829B1/en active Active
- 2018-05-03 JP JP2019560299A patent/JP7295034B2/en active Active
- 2018-05-03 US US16/610,812 patent/US11045472B2/en active Active
- 2018-05-03 WO PCT/US2018/030909 patent/WO2018204661A1/en active Application Filing
- 2018-05-03 PL PL18794742.9T patent/PL3618829T3/en unknown
- 2018-05-04 UY UY0001037725A patent/UY37725A/en not_active Application Discontinuation
- 2018-05-04 TW TW107115270A patent/TWI789393B/en active
Also Published As
Publication number | Publication date |
---|---|
US11045472B2 (en) | 2021-06-29 |
CN110612100B (en) | 2023-04-14 |
TW201843150A (en) | 2018-12-16 |
EP3618829A1 (en) | 2020-03-11 |
TWI789393B (en) | 2023-01-11 |
CN110612100A (en) | 2019-12-24 |
UY37725A (en) | 2018-10-31 |
JP2020518627A (en) | 2020-06-25 |
US20200069689A1 (en) | 2020-03-05 |
PL3618829T3 (en) | 2023-11-20 |
EP3618829B1 (en) | 2023-06-07 |
JP7295034B2 (en) | 2023-06-20 |
EP3618829A4 (en) | 2021-01-06 |
WO2018204661A1 (en) | 2018-11-08 |
ES2953349T3 (en) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
EP3618829C0 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
EP3634417C0 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
IL271085A (en) | Bacteria for the treatment of disorders | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
IL259996A (en) | Combinations for the treatment of cancer | |
HK1256721A1 (en) | Compounds and compositions for the treatment of ocular disorders | |
IL267818A (en) | Methods for the treatment of neurological disorders | |
IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | |
IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
IL259674B (en) | Benzofuran derivatives for the treatment of cns and other disorders | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
EP3371154A4 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
IL273835A (en) | Combination product for the treatment of cancer | |
EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
PL3630754T3 (en) | Isoindoline-acetylene compounds for the treatment of cancer | |
EP3538102A4 (en) | Inhibition of kmt2d for the treatment of cancer | |
PT3580211T (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
GB201602784D0 (en) | New treatment of CFTR-related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40024629 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/517 20060101ALI20201127BHEP Ipc: A61K 31/44 20060101AFI20201127BHEP Ipc: C07D 231/10 20060101ALI20201127BHEP Ipc: A61K 31/497 20060101ALI20201127BHEP Ipc: C07D 403/00 20060101ALI20201127BHEP Ipc: C07D 239/72 20060101ALI20201127BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602018051283 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031440000 Ipc: C07D0231100000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20220920BHEP Ipc: A61K 31/517 20060101ALI20220920BHEP Ipc: A61K 31/497 20060101ALI20220920BHEP Ipc: A61K 31/44 20060101ALI20220920BHEP Ipc: C07D 403/00 20060101ALI20220920BHEP Ipc: C07D 239/72 20060101ALI20220920BHEP Ipc: C07D 231/10 20060101AFI20220920BHEP |
|
INTG | Intention to grant announced |
Effective date: 20221017 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1574694 Country of ref document: AT Kind code of ref document: T Effective date: 20230615 Ref country code: DE Ref legal event code: R096 Ref document number: 602018051283 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20230704 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230714 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20230607 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20230401336 Country of ref document: GR Effective date: 20231010 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2953349 Country of ref document: ES Kind code of ref document: T3 Effective date: 20231110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 42489 Country of ref document: SK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018051283 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240312 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240314 Year of fee payment: 7 Ref country code: SK Payment date: 20240326 Year of fee payment: 7 |
|
26N | No opposition filed |
Effective date: 20240308 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20240412 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240602 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240611 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20240417 Year of fee payment: 7 |
|
U21 | Renewal fee paid with penalty [unitary effect] |
Year of fee payment: 7 Effective date: 20240619 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20240508 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20240315 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20240419 Year of fee payment: 7 |